Plotka A
Tanzania
Research Article
Pharmacokinetics and Tolerability of Single and Multiple Doses of Desvenlafaxine
in Healthy Korean Subjects
Author(s): Liang Y, Qiu R, Kim S, Jang IJ, Lee WS, Plotka A and Nichols A
Liang Y, Qiu R, Kim S, Jang IJ, Lee WS, Plotka A and Nichols A
Background: Racial and ethnic variations in CYP enzyme polymorphisms have been associated with population differences in drug metabolism. This study evaluated the pharmacokinetics of single- and multiple-dose desvenlafaxine in healthy Korean subjects.
Methods: This randomized, double-blind, placebo-controlled, study enrolled 38 healthy Korean adults (aged 18 to 55 years). Subjects received single oral doses of placebo or desvenlafaxine (administered as desvenlafaxine succinate) 50, 100, or 200 mg on day 1, followed by 5 days of once daily dosing on days 4 to 8. Blood samples were collected pre-dose and over 72 h post-dose on days 1 and 8. Plasma desvenlafaxine concentrations were measured using a validated high-performance liquid chromatography tandem mass spectrometry and pharmacokinetic parameters were calculated using non-compartmental me.. View More»
DOI:
10.4172/jbb.1000322